Clinical Scorecard: Influence of Mitochondrial DNA Variability and Antiretroviral Treatment on Diabetes Risk in Men With and Without HIV

At a Glance

Key Highlights

• African mtDNA haplogroup L3 is associated with a higher risk of incident type 2 DM in men with HIV.
• Exposure to mitochondrial-toxic ART (D-drugs such as stavudine, zalcitabine, didanosine) independently increases DM risk in men with HIV.
• Mitochondrial dysfunction contributes to impaired insulin release and increased DM prevalence in people with HIV.

Guideline-Based Recommendations

Diagnosis

• Define type 2 DM by fasting glucose ≥126 mg/dL, hemoglobin A1c ≥6.5%, DM medication use, or clinical diagnosis.

Management

• Consider history of exposure to mitochondrial-toxic ART when assessing DM risk in men with HIV.
• Monitor and potentially avoid use of D-drugs due to their mitochondrial toxicity and associated increased DM risk.

Monitoring & Follow-up

• Routine fasting glucose and hemoglobin A1c measurements in men with HIV, especially those with African mtDNA haplogroup L3 or prior D-drug exposure.

Risks

• Mitochondrial-toxic ART (D-drugs) increases risk of incident DM.
• African mtDNA haplogroup L3 confers higher susceptibility to DM in men with HIV.

Patient & Prescribing Data

Men with HIV, including those of African and European mtDNA haplogroups

Prior exposure to mitochondrial-toxic NRTIs (D-drugs) is associated with nearly threefold increased risk of developing type 2 DM.

Clinical Best Practices

• Assess mitochondrial DNA haplogroup status as a potential risk factor for DM in men with HIV.
• Avoid or limit use of mitochondrial-toxic ART agents when possible to reduce DM risk.
• Implement regular metabolic screening for early detection of DM in aging men with HIV.
• Adjust clinical management plans considering both genetic susceptibility and ART exposure history.

References

• Multicenter AIDS Cohort Study (MACS)
• HaploGrep mtDNA Haplogroup Determination